The α5β1 Integrin Mediates Elimination of Amyloid-β Peptide and Protects Against Apoptosis by Matter, Michelle L. et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/98/05/1019/12 $2.00
The Journal of Cell Biology, Volume 141, Number 4, May 18, 1998 1019–1030
http://www.jcb.org 1019
 
The 
 
a
 
5
 
b
 
1 Integrin Mediates Elimination of Amyloid-
 
b
 
Peptide and Protects Against Apoptosis
 
Michelle L. Matter,* Zhuohua Zhang,*
 
‡
 
 Christer Nordstedt,
 
§
 
 and Erkki Ruoslahti*
 
 
 
*La Jolla Cancer Research Center, The Burnham Institute, La Jolla, California 92037; 
 
‡
 
Department of Neurobiology, Harvard 
Medical School, and Division of Neuroscience, The Children’s Hospital, Boston, Massachusetts 02115; and 
 
§
 
Department of 
Clinical Neuroscience, The Karolinska Hospital, Stockholm, Sweden S-171 76
 
Abstract. 
 
The amyloid-
 
b
 
 peptide (A
 
b
 
) can mediate 
cell attachment by binding to 
 
b
 
1 integrins through an 
arg-his-asp sequence. We show here that the 
 
a
 
5
 
b
 
1 inte-
grin, a fibronectin receptor, is an efficient binder of A
 
b
 
, 
and mediates cell attachment to nonfibrillar A
 
b
 
. Cells 
engineered to express 
 
a
 
5
 
b
 
1 internalized and degraded 
more added A
 
b
 
1-40 than did 
 
a
 
5
 
b
 
1-negative control 
cells. Deposition of an insoluble A
 
b
 
1-40 matrix around 
the 
 
a
 
5
 
b
 
1-expressing cells was reduced, and the cells 
showed less apoptosis than the control cells. Thus, the 
 
a
 
5
 
b
 
1 integrin may protect against A
 
b
 
 deposition and 
toxicity, which is a course of Alzheimer’s disease le-
sions.
 
I
 
ntegrin
 
-mediated cell adhesion is necessary for the
survival of many types of cells, and loss of adhesion
causes apoptosis (reviewed in Frisch and Ruoslahti,
1997). The 
 
a
 
5
 
b
 
1 integrin may have a particularly promi-
nent antiapoptotic effect because 
 
a
 
5
 
b
 
1 is the only integrin
that protects cells from apoptosis in serum-free cultures
(Zhang et al., 1995; O’Brien et al., 1996). 
 
a
 
5
 
b
 
1-mediated
adhesion upregulates the antiapoptosis protein Bcl-2 (Zhang
et al., 1995), and 
 
a
 
5
 
b
 
1 is one of a few integrins that acti-
vates the signaling protein Shc (Wary et al., 1996). These
signaling events may partly explain its antiapoptotic ef-
fects.
 
b
 
1 integrins have been shown to mediate cell adhesion
to the amyloid beta (A
 
b
 
)
 
1
 
 protein, and 
 
a
 
5
 
b
 
1 has been pro-
posed to be the integrin responsible for the A
 
b
 
 binding
(Ghiso et al., 1992). The amino acid sequence arg-his-asp
(RHD) has been pinpointed as the integrin recognition
site in A
 
b
 
 (Ghiso et al., 1992; Sabo et al., 1995). This se-
quence resembles the general integrin recognition se-
quence RGD present in many extracellular matrix pro-
teins (Ruoslahti, 1996
 
a
 
).
A
 
b
 
 is a 39–42 amino acid protein derived from pro-
teolytic cleavage of a larger membrane-spanning glycopro-
tein, the amyloid precursor protein (APP; Kang et al.,
1987). A
 
b
 
 forms fibrillar aggregates that can cause cell
death by apoptosis (Loo et al., 1993; Pike et al., 1993;
Lorenzo and Yanker, 1994). Enhanced deposition of A
 
b
 
matrix within the cortex, hippocampus, and vasculature of
the brain correlates with neuronal cell death and ulti-
mately dementia in Alzheimer’s disease (AD; reviewed by
Selkoe, 1994). Two predominant forms of A
 
b
 
 (1–40 and
1–42) exist in AD that differ by two amino acid residues at
the hydrophobic COOH terminus, a domain that is re-
quired for nucleation-dependent fibril formation (Jarret
et al., 1993). The A
 
b
 
1-40 form has a slower rate of fibril
formation in vitro than the A
 
b
 
1-42 form (Jarret et al.,
1993).
There is evidence for three mechanisms of A
 
b
 
 accumu-
lation: overproduction of A
 
b
 
, production of longer forms
of A
 
b
 
 (which aggregate more), and impaired clearance of
A
 
b
 
. The clearance pathways for fibrillar and soluble A
 
b
 
are incompletely known. Two cell surface receptors are
known to bind A
 
b
 
. The scavenger receptor present on
glial cells binds specifically to fibrillar A
 
b
 
, and appears to
mediate clearance of small fibrillar A
 
b
 
 aggregates in vitro
(Paresce et al., 1996; Khoury et al., 1996). The receptor for
advanced glycation end products binds both the soluble
and fibrillar forms of A
 
b
 
, and may mediate some of the cy-
totoxic effects of fibrillar A
 
b
 
 (Yan et al., 1996).
Because 
 
a
 
5
 
b
 
1 may also be an A
 
b
 
 receptor, and because
 
a
 
5
 
b
 
1 and A
 
b
 
 have apparently contrasting effects on apop-
tosis, we sought to determine whether 
 
a
 
5
 
b
 
1 is indeed an
A
 
b
 
-binding integrin and, if so, what effect it might have on
the metabolism of A
 
b
 
 and on cell survival. We show here
that nonfibrillar A
 
b
 
 binds to the 
 
a
 
5
 
b
 
1 integrin, and that
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b
 
 peptide; AD,
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this interaction promotes clearance of A
 
b
 
 by cultured
cells, reducing the formation of an insoluble A
 
b
 
 fibrillar
matrix and counteracting the toxic effects of the A
 
b
 
 ma-
trix. These results suggest a new function for 
 
a
 
5
 
b
 
1 as a
binder of A
 
b
 
 and a regulator of brain cell survival.
 
Materials and Methods
 
Cells
 
The human neuroblastoma cell line (IMR-32) was obtained from the
American Type Culture Collection (Rockville, MD). The CHO-B2 cells
deficient in 
 
a
 
5
 
b
 
1 were from Dr. Rudolf Juliano (School of Medicine, Uni-
versity of North Carolina, Chapel Hill, NC; Schreiner et al., 1989). All
cells were maintained in 
 
a
 
-MEM (Sigma Chemical Co., St. Louis, MO)
supplemented with 10% FBS and glutamine/pen-strep (Irvine Scientific,
Santa Ana, CA). G418 (GIBCO BRL, Gaithersburg, MD) was added to
the media of transfected cells at a concentration of 250 
 
m
 
g/ml.
 
Reagents
 
Amyloid beta 1-40 peptide (A
 
b
 
) was synthesized as previously described
(Nordstedt et al., 1994). A
 
b
 
 was also purchased from a commercial source
(Synthetic Amyloid Beta peptide 1–40; Bachem, Torrance, CA). A
 
b
 
1-40
from both sources was examined for cell adhesion activity. Two out of the
three Bachem lots tested showed adhesive activity (lots zn571 and
wm365), while lot zn327 was not active. For water-free storage to prevent
aggregation of A
 
b
 
 into its fibrillar form, the peptide was dissolved and
stored in 1,1,1,3,3,3,-hexafluoro-2-propanol (HFIP; Fluka Chemika, Neu-
Ulm, Switerland). Before use, the peptide was lyophilized from HFIP, dis-
solved in sterile distilled water at 1 mg/ml, and tested immediately. The
control peptide, A
 
b
 
40-1, was purchased from Bachem, solubilized in wa-
ter at 1 mg/ml, and tested immediately. Fibronectin was purchased from
Chemicon International, Inc. (Temecula, CA), and vitronectin was puri-
fied as described (Yatohgo et al., 1988). Purified anti-human 
 
a
 
5 integrin
monoclonal antibody (P1D6; Calbiochem-Novabiochem Corp., La Jolla,
CA; Wayner et al., 1988) and purified mouse IgG (Sigma Chemical Co.)
were used at a concentration of 50 
 
m
 
g/ml.
 
Transfection
 
The CHO-B2/
 
a
 
5
 
b
 
1
 
1
 
, CHO-B2/
 
a
 
v
 
b
 
1
 
1
 
, and IMR-32/
 
a
 
5
 
b
 
1
 
1
 
 cells were gen-
erated by introducing cDNAs coding for the 
 
a
 
5 and 
 
a
 
v integrin subunits
into 
 
a
 
5
 
b
 
1-deficient CHO-B2 and IMR-32 cells (Schreiner et al., 1989;
Bauer et al., 1992; Zhang et al., 1993, 1995). Transfectants expressing the
integrin were cloned and expanded (Zhang et al., 1993; Zhang et al.,
1995). CHO-B2 and IMR-32 control cells received the empty vector.
 
Integrin Analysis
 
Integrin expression of IMR-32 and CHO transfectants was analyzed by
FACS using monoclonal antibodies against human 
 
a
 
5 (P1D6), 
 
a
 
v (L230),
and 
 
b
 
1 (P4C10). FITC-conjugated goat anti–mouse antibody (Sigma
Chemical Co.) was used as the secondary antibody. The same integrin an-
tibodies were used to block integrin function in other experiments.
 
Cell Adhesion to Nonfibrillar A
 
b
 
1-40
 
The cell attachment assay and the use of antibodies and peptides as inhib-
itors of adhesion have been described previously (Zhang et al., 1993; Mat-
ter and Laurie, 1994). Microtiter plates coated overnight at room temper-
ature with nonfibrillar Ab1-40 peptide, control Ab40-1 peptide, or
fibronectin were blocked with 1% BSA for 30 min at room temperature,
the wells were rinsed once with PBS (pH 7.4), and cells were subsequently
added (2 3 10 5 cells/well) in serum-free media and incubated for 60 min
(378C). Inhibition studies were performed by preincubating cells with anti-
body for 30 min (378C; gentle agitation every 10 min), and then cells in-
cluding antibodies were added to the coated wells. After a 60-min incuba-
tion at 378C, plates were gently washed four times with PBS, fixed with
1% glutaraldehyde (Sigma Chemical Co.), PBS-washed once, stained with
0.5% crystal violet, 20% MEOH, washed under running distilled water,
solubilized in 0.1 N sodium citrate, 50% ETOH, and read on an ELISA
plate reader (Molecular Devices Corp., Sunnyvale, CA) using the 590-nm
filter.
Adhesion assays with fibrillar Ab1-40 were performed as above. Be-
fore the adhesion assay, soluble Ab1-40 was incubated at 48C for 96 h to
allow self-aggregation of Ab1-40 into its fibrillar form (Jarret et al., 1993).
Coating efficiency was measured by coating microtiter wells with either
soluble [125I]Ab1-40 or preaggregated [125I]Ab1-40 at room temperature
overnight. Nonbound peptide solution was removed, and the well and the
nonbound peptide solution were counted. Both forms of Ab1-40 bound to
the wells with an efficiency of z70%.
Immunostaining of Ab Fibrillar Matrix
Cells were plated on four-well Permanox™ plastic slides (Nunc Inc., Na-
perville, IL) at 50,000 cells/well. 6 h after plating, the media was replaced
with media containing Ab1-40 peptide (100 mg/ml) and incubated for 72 h
at 378C. The cultures were washed with PBS and fixed in PBS containing
3.7% paraformaldehyde and 10 mM sucrose, pH 7.4, for 30 min at room
temperature. The cultures were then blocked with 1% BSA/PBS and
stained with a polyclonal rabbit anti-human Ab1-40 peptide antibody
(Chemicon International, Inc.) for 2 h, followed by goat anti–rabbit FITC-
labeled IgG (Sigma Chemical Co.) secondary antibody. After antibody
treatment, coverslips were mounted with Vectashield mounting medium
(Vector Labs., Inc., Burlingame, CA) and analyzed under a fluorescent
confocal microscope.
Analysis of Ab in Matrix Deposition with
Radiolabeled [125I]Ab
125I-labeled Ab1-40 peptide was purchased as a lyophilized powder (25
mCi) from Nycomed Amersham, Inc. (Princeton, NJ). The powder was
solubilized in sterile water and immediately added to 24-well culture
dishes at a concentration of 2 ng/well. The specific activity of the 125I-labeled
Ab1-40 peptide was 2 3 106 mCi/mmol.
Insolubilization of Ab was analyzed using 125I-labeled Ab1-40 peptide
as described previously for fibronectin matrix assembly (McKeown-
Longo and Mosher, 1985; Morla and Ruoslahti, 1992). Cells were plated at
105 cells/ml (IMR variants) or 0.5 3 105 cells/ml (CHO variants) into 24-
well tissue culture plates in media containing 10% serum. Media was re-
placed 6 h after plating with media containing [125I]Ab1-40 and 10% se-
rum. Cells were cultured for 72 h at 378C. The media was then removed,
the wells were washed three times with PBS, and 53 SDS sample buffer
(0.5M Tris pH 6.8, glycerol, 10% SDS, 0.5% bromophenol blue) was used
to solubilize the [125I]Ab matrix in each well.
For antibody inhibition experiments, cells were plated as above. 6 h af-
ter plating, the media was replaced with media containing the appropriate
antibody and 10% serum. 125I-labeled Ab1-40 peptide (2 ng/well) was
added to the antibody-containing media and incubated for 72 h at 378C.
The cells were then processed as above.
Internalization and Degradation of
[125I]Soluble Ab1-40
Internalization of Ab1-40 added to cell layers was measured as described
(Duckworth et al., 1972; McDermott and Gibson, 1997). Subconfluent
cells were trypsinized and plated onto 24-well plates. Media was replaced
6 h after plating with [125I]Ab1-40 (2 ng/ml). The cells were incubated for
1 h with [125I]Ab1-40, the media was removed, cells were washed five
times with PBS, and serum-containing media containing no Ab1-40 was
added. The cells were cultured for 1 to 12 h at 378C, washed three times
with PBS, detached by EDTA, washed twice with PBS, lysed in 100 ml of
1% NP40 buffer for 10 min at 48C, and lysate-analyzed for radioactivity.
For TCA precipitations, the cells were cultured for 72 h with [125I]Ab1-40
at 378C, washed three times with PBS, detached by EDTA, washed twice
with PBS, and lysed in 100 ml of 1% NP40 buffer for 10 min at 48C. BSA/
PBS (100 ml, 1%) was added to the samples, the samples were vortexed,
and 1.6 ml of TCA (12.5% wt/vol) was added with vortexing. The samples
were centrifuged at 2,000 rpm for 10 min at 48C, and the supernatant and
pellet were collected for radioactive counting.
Secretion of 125I-Labeled Ab1-40
Subconfluent cells were detached with trypsin, washed once with media,
and plated at 105 cells/ml in 24-well plates. 6 h after plating, media was re-
placed with 2 ng/ml of [125I]Ab1-40 in serum-containing media and incu-
bated for 1 h at 378C. The radiolabeled media was removed, and cells wereMatter et al. Integrin Mediated Internalization of Soluble Amyloid-b 1021
Figure 1. Integrins mediate CHO cell adhesion to nonfibrillar
Ab. Adhesion of CHO cells to coated Ab1-40 was measured. The
cells were transfected with human a5 or av integrin subunit
cDNA. (A) The cells were seeded onto various concentrations
of coated Ab1-40. (B) Cells were plated onto Ab1-40 coated in
its soluble form, Ab1-40 coated after self-aggregation into its
fibrillar form, or on the control peptide Ab40-1. (C) Cells were
preincubated with either the blocking monoclonal antibodies to
human a5 (P1D6), human av (L230), the integrin-binding pep-
tideGRGDSP, or the control peptide GRGESP, and then seeded
onto coated soluble Ab1-40. After a 60-min incubation at 378C,
attached cells were quantitated. Values represent the mean 6
SD; n 5 9.The Journal of Cell Biology, Volume 141, 1998 1022
washed five times in PBS before serum-containing media containing no
Ab was added to each well. At designated time points, 100 ml of media
was collected, and [125I] was measured.
Apoptosis and Cell Viability Assays
The apoptotic effect of fibrillar Ab was determined using the Apoptag
Plus In Situ Apoptosis Kit™ (Oncor, Inc., Gaithersburg, MD) that detects
the 39-OH region of cleaved DNA. Cells were plated on eight-chamber
tissue culture glass slides (Miles Scientific Laboratories, Inc., Naperville,
IL), and 6 h after plating the media was replaced with media containing ei-
ther Ab1-40 peptide (50 mg/ml) or Ab40-1 control peptide (50 mg/ml) and
10% serum. Cells were cultured for 72 h at 378C, and were then fixed in a
solution containing 3.7% paraformaldehyde, 10 mM sucrose in PBS for 30
min at room temperature. Cells were stained following kit protocol, coun-
terstained with propidium iodide/antifade solution (Oncor, Inc.), mounted,
and viewed under a confocal microscope.
To measure apoptosis by nuclear fragmentation, cells were plated in
wells coated with either 50 mg/ml of fibronectin, vitronectin, or Ab1-40 for
72 h in serum-free medium. Attached and floating cells were then col-
lected by centrifugation, washed once with PBS, fixed with 3.7%
paraformaldehyde for 10 min at room temperature, and stained with 0.1 mg
of 49, 6-diamidino-2-phenylindole (DAPI) per ml in PBS. The stained cells
were washed three times with PBS and mounted onto slides for analysis
under a fluorescence microscope (Zhang et al., 1995).
Cell viability was assessed in several assays. The ability of cells to take
up acridine orange/ethidium bromide was measured as described (Cotter
and Martin, 1996). In brief, the assay was performed in 96-well tissue cul-
ture plates containing 100 ml media/well. Cells were plated in media con-
taining 10% serum. 6 h after plating, the media was replaced with media
containing various concentrations of the test reagents and 10% serum.
The plates were incubated for 72 h at 378C. At the 72-h time point, cells
were trypsinized and resuspended in PBS at 0.5 3 106 cells/ml. 1 ml from a
solution of acridine orange (100 mg/ml) and ethidium bromide (100 mg/ml)
was added to a 25-ml cell suspension, incubated for 2 min at room temper-
ature, and examined under 403 magnification using a Zeiss Fluorescence
microscope.
Cells cultured in microtiter wells were pulsed with 25 ml of a 2.5 mg/ml
MTT stock in PBS and incubated for 4 h. Then 100 ml of a solution con-
taining 10% SDS, 0.01 N HCl was added, and the plates were incubated
overnight (Tada et al., 1986). Absorption was read on a Vmax Microplate
Reader™ (Molecular Devices Corp., Sunnyvale, CA) using a reference
wavelenth of 650 nm and a test wavelength of 590 nm. Test reagents were
added to media alone in order to provide a blank.
To measure lactate dehydrogenase (LDH) release from cells, the color-
imetric Cytotox 96-LDH-Release Assay™ (Promega Corp., Madison, WI)
was performed according to the instructions of the manufacturer.
Figure 2. FACS analysis of
a5b1 integrin expression on
IMR-32 neuroblastoma cells
and CHO cells. a5b1 surface
expression by three IMR-32
cell clones transfected with
human a5 cDNA. IMR-32/
a5b1 clone 4 (A), IMR-32/
a5b1 clone 15 (B), and IMR-
32/a5b1 clone 16 (C; solid
lines) is compared with a vec-
tor-transfected control line
IMR32/c (A and B; dashed
lines), and the parental cell
line IMR-32/p (C; dashed
line). (D) CHO cells trans-
fected with the human a5
cDNA express a5b1 on their
surface (solid line), whereas
the vector-transfected con-
trol cells (CHO-B2/c) do not
(dashed line). Cells were
stained with a monoclonal
antibody to the human a5 in-
tegrin subunit, followed by
an FITC-labeled secondary
antibody, and analyzed by
FACS. (E) CHO cells trans-
fected with the human av
cDNA express avb1 on their
surface (solid line), whereas
the vector-transfected con-
trol cells (CHO-B2/c) do not.
The staining was with a mono-
clonal antibody to the human
av integrin subunit.Matter et al. Integrin Mediated Internalization of Soluble Amyloid-b 1023
Results
The Integrin a5b1 Mediates Cell Adhesion to 
Nonfibrillar Ab1-40
The RHD sequence in Ab resembles the integrin recogni-
tion sequence RGD, and has been implicated in cell adhe-
sion to Ab via one or more of the b1 integrins (Ghiso et al.,
1992; Sabo et al., 1995). We set out to determine which of
the RGD-binding integrins bind to Ab. A CHO cell line
deficient in a5 integrin subunit expression (CHO-B2) was
transfected with cDNA encoding human a5, av, or vector
alone, and was examined for its ability to adhere to a sur-
face coated with Ab1-40. Each of the integrin transfec-
tants adhered to Ab in a dose-dependent manner, but cells
that received the vector alone attached to Ab within the
BSA background range (Fig. 1 A). CHO-B2/a5b11 cells
adhered strongly to Ab, and CHO-B2/avb11 cells were
moderately adhesive, whereas the control cells CHO-B2/c
did not adhere above BSA background levels. FACS anal-
ysis indicated that CHO-B2/a5b11 and CHO-B2/avb11
cell transfectants were similar in their expression of the
transfected integrin (Fig. 2, D and E). A control peptide in
which the Ab sequence is inverted (Ab40-1) did not have
adhesive activity with any of the cell types tested (Fig. 1 B).
In addition, integrin transfectants adhered only to soluble
nonfibrillar Ab1-40, and not to fibrillar Ab1-40 (Fig. 1 B).
Plates were coated with equal amounts of soluble and
fibrillar Ab1-40 as measured by [125I]Ab1-40. The a5b1-
mediated cell adhesion to soluble Ab1-40 was inhibitable
by the integrin-binding peptide GRGDSP, and by a func-
tion-blocking anti-a5 integrin monoclonal antibody (P1D6;
Fig. 1 C), but not by the control peptide GRGESP or a
monoclonal antibody to av (Fig. 1 C). The avb3 integrin,
which also binds to RGD, does not mediate adhesion to Ab
because avb3-expressing IMR-90 cells did not adhere to
Ab when the a5b1 and avb1 integrins were blocked with
anti-a5 and anti-b1 monoclonal antibodies (data not shown).
We also tested the a5-negative human neuroblastoma
cell line IMR-32 (Neill et al., 1994) for Ab attachment
with (IMR-32/a5b11) and without (IMR-32/c) a5 trans-
fection (Fig. 2 A). Three separate clones were obtained
that expressed human a5b1 on their surface as detected by
FACS analysis (Fig. 2, A–C). Each a5b1-expressing clone
adhered to coated Ab1-40 in a dose-dependent manner
(Fig. 3 A), and cell adhesion was inhibitable by an anti-a5
antibody (data not shown). The control-transfected IMR-32
cells (Fig. 2, A–C) attached poorly to this substrate (Fig. 3
A). Both the transfected and control cells attached well to
vitronectin (data not shown), whereas the control peptide
Ab40-1 and fibrillar Ab1-40 did not promote adhesion
above BSA background levels for any of the IMR-32 cell
lines (Fig. 3 B).
a5b1 Reduces the Formation of an Insoluble Ab 
Fibrillar Extracellular Matrix
An increase of insoluble Ab fibrillar matrix is one hall-
mark of AD (Glenner and Wong, 1984; Masters et al.,
1985). As shown above, the a5b1 integrin bound to coated
Ab with the highest avidity among the integrins we tested.
Therefore, we asked whether a5b1 would affect the for-
mation of an Ab fibrillar matrix. Exogenous Ab1-40
Figure 3. Adhesion of IMR-32 cells to coated Ab. (A) Adhesion
of IMR-32 cells transfected with the human a5 subunit IMR-32/
a5b1 and vector-transfected IMR-32/c cells to Ab1-40 was mea-
sured as described in the legend for Fig. 1. (B) IMR-32 cell trans-
fectants and control IMR-32/c and IMR-32/p cells were plated on
Ab1-40 coated in its soluble or fibrillar form or on the control
peptide Ab40-1, and cell adhesion was measured as described in
the legend for Fig. 1. Values in A and B represent the mean 6
SD; n 5 9.The Journal of Cell Biology, Volume 141, 1998 1024
added to cell cultures formed a matrix around the cells
that was detectable by immunostaining with anti-Ab anti-
bodies. There was a substantial decrease in the formation
of matrix from added Ab in cultures of the a5b1-express-
ing IMR-32 cell lines compared with the control lines (Fig.
4, A–D). Moreover, the matrix in the a5b11 cell cultures
appeared to be cell-associated, whereas in the a5b12 cell
cultures it appeared to be largely independent of the cells.
To study quantitatively the formation of the Ab matrix,
the various IMR-32 lines were incubated with 125I-labeled
Ab for 72 h, and the amount of radiolabeled Ab that had
become soluble in detergent was measured. The IMR-32
clones expressing a5b1 deposited fivefold less insoluble
Ab radioactivity than the control cells. Moreover, the
P1D6 anti-a5 antibody returned Ab matrix formation in
the a5b1-expressing IMR-32 cultures to the level in the
parental control cells (Fig. 5 A). A control antibody had
no effect. CHO cells expressing a5b1 also had less Ab ma-
trix than their control-transfected counterpart cells as
judged from the insolubility of [125I]Ab; the difference was
fourfold (Fig. 5 B). Adding the anti-a5 antibody canceled
the a5b1 effect, but a control antibody did not. The insolu-
bility of Ab remained the same in the CHO control cell
cultures regardless of the antibody added. These results in-
dicate that cell expression of a5b1 reduces Ab matrix dep-
osition threefold relative to the control cells. Because iodi-
nated Ab forms fibrils less readily than unlabeled Ab1-40
(Bush et al., 1994), it was not possible to use the [125I]Ab
to quantitate the proportion of the added Ab1-40 that be-
comes insolubilized.
Soluble Ab1-40 is Taken Up By Cells and Partially 
Degraded Via an a5b1-Mediated Pathway
Possible reasons for the a5b1-mediated reduction of Ab
matrix include internalization of soluble Ab1-40, degrada-
tion of the peptide, or both. Neuronal cells have been
shown to internalize Ab, but the mechanism for this inter-
nalization is only incompletely known (Ida et al., 1996,
Hammad et al., 1997). To investigate the possibility that
binding a5b1 to soluble Ab initiates cellular uptake of Ab,
we examined the processing of 125I-labeled Ab1-40 by
a5b11 and a5b12 cells. Initially, CHO-B2/c control cells
and transfectants were incubated for 1 h with [125I]Ab1-40,
and were then examined for cell-associated radioactivity.
The  a5b1-expressing CHO-B2 cells contained twofold
more radioactivity at 1 and 12 h than the control CHO-B2/c
cells (Fig. 6 A).
Cell cultures were then incubated with 125I-labeled Ab
over a 72-h period to determine whether the [125I]Ab
taken up by the cells was degraded. a5b1-expressing IMR-32
cells contained twofold more radioactivity after the 72-h in-
Figure 4. Immunofluorescent
detection of reduced Ab matrix
in cultures expressing the a5b1
integrin. Deposition of Ab1-40
matrix from soluble Ab added
to the culture media of IMR-32
control cells IMR-32/c (A) and
IMR-32/p (B), and of a5b1 ex-
pressing IMR-32 clones 4 (C)
and 15 (D) was examined. The
Ab matrix was detected by a
polyclonal anti-Ab1-40 antibody
followed by a rhodamine-labeled
secondary antibody. The experi-
ment was repeated at least three
times for each cell line, and rep-
resentative results are shown.
Bar, 50 mm.Matter et al. Integrin Mediated Internalization of Soluble Amyloid-b 1025
cubation than a5b1-negative IMR-32 cells (Fig. 6 B). Part
of the radioactivity was soluble in TCA, indicating that Ab
had been degraded. CHO cells internalized and degraded
soluble Ab in a similar manner, with a5b1-expressing cells
containing eightfold more TCA-soluble radioactivity than
a5b1-negative cells (Fig. 6 C). The CHO cells expressing
a5b1 bound 10% of the added Ab, whereas the control
cells bound only 0.4%. Moreover, 90% of the cell-associ-
ated Ab was degraded in the CHO-a5b1 expressers. The
higher expression levels of a5b1 on the CHO transfectants
(Fig. 2, D and E) may explain why these cells bound and
internalized more radiolabeled Ab than the IMR-32 trans-
fectants.
We next examined whether Ab was released into the
culture medium. The release of radioactivity into cell cul-
ture media was monitored over a 72-h period that fol-
lowed a 1-h incubation with 125I-labeled Ab1-40. The me-
dia of a5b1-expressing IMR-32 and CHO cells contained
twofold more radioactivity than the corresponding control
cell media (Fig. 6, D and E). These results point to an
a5b1-dependent pathway that internalizes and degrades Ab.
a5b1 Protects Cells Against Ab Induced Apoptosis
Having established an a5b1-dependent mechanism for the
inhibition of Ab matrix deposition, we examined whether
the reduction of the Ab matrix would promote neuronal
cell survival in cultures treated with Ab. IMR-32 cell lines
cultured with exogenous soluble Ab1-40 underwent apop-
tosis in the absence of a5b1 (Fig. 7, A and B), but three
a5b1-expressing lines did not (two are shown in Fig. 7, C
and D). The control peptide Ab40-1 caused no apoptosis
in the control (Fig. 7, E and F) or a5b1-expressing cells
(not shown). Analysis of acridine orange/ethidium bro-
mide uptake revealed three times more apoptosis in the
control cells than in the IMR-32 a5b1-expressers (Fig. 8).
We also assessed the Ab effect by using the MTT assay,
which measures cell viability by detecting the ability of a
mitochondrial enzyme to reduce its substrate. Ab-treated
IMR-32 control cells lost their ability to reduce MTT in a
manner that was dependent on the dose of Ab, whereas
Ab had almost no effect on the a5b1-expressing cell lines
(Fig. 9 A). The control peptide Ab40-1 had no effect on
MTT reduction in any of the cell types, even at the highest
test concentration (Fig. 9 B). To examine further the cyto-
toxicity of Ab1-40, we used an assay that measures the re-
lease of LDH upon cell lysis (Behl et al., 1994). A three-
fold increase in LDH levels relative to controls was seen in
the a5b12 IMR-32 cells cultured in the presence of Ab1-
40, whereas Ab1-40 had no effect on the LDH levels of the
a5b11 cells (Fig. 10 A). These results indicate that a5b1-
mediated Ab binding protects the IMR-32 cells from the
cytotoxicity of aggregated Ab, presumably by inhibiting its
aggregation into fibrils. No apoptosis was caused by Ab in
any of the CHO cell lines, as examined by TUNEL stain-
ing, the MTT assay, and the LDH assay, indicating that
these cells are resistant to the cytotoxic effects of an Ab
matrix.
We previously demonstrated that cell attachment through
a5b1 protects CHO cells from apoptosis when cultured in
a serum-free environment (Zhang et al., 1995). Therefore,
we examined whether ligation of a5b1 to coated Ab1-40
Figure 5. Quantitation of Ab
matrix deposition in cultures
of IMR-32 cells and their
a5b1-expressing clones. (A)
125I-labeled soluble Ab1-40
was incubated with cultures
of two control lines and three
a5b1-expressing lines at 378C
for 72 h in the presence of ei-
ther the monoclonal anti-
body to the human a5 in-
tegrin subunit (P1D6) or
control IgG. The total
amount of 125I-labeled Ab1-40
associated with an SDS solu-
ble matrix was determined as
described in Materials and
Methods. The reduction of
Ab1-40 matrix deposition in
the a5b1-expressing cultures
was reversed by an anti-a5
integrin monoclonal antibody
(P1D6), but not by the con-
trol IgG. (B) CHO-B2/a5b1
cells show reduced deposi-
tion of [125I] to Ab matrix rel-
ative to control CHO cells.
The experimental procedure
was the same as in A. The
P1D6 antibody reversed the a5b1-dependent matrix reduction, whereas the control mouse IgG had no effect. Experiments in A and B
were repeated at least four times, and representative results are shown. Values represent the mean 6 SD; n 5 3.The Journal of Cell Biology, Volume 141, 1998 1026
would protect a5b1-expressing CHO cells from apoptosis
in serum-free cultures. CHO-B2/a5b11 cells were plated
on either fibronectin, vitronectin, or Ab-coated dishes and
examined for survival 96 h after serum withdrawal. CHO-
B2/a5b11 cells survived on Ab and fibronectin, whereas
cells plated on vitronectin underwent apoptosis (Fig. 10
B). These results indicate that a5b1 can also protect cells
from apoptosis by mediating cell attachment to coated Ab.
Discussion
We report that the a5b1 integrin mediates cell adhesion to
Ab and promotes internalization and degradation of Ab.
This a5b1–Ab interaction correlates with both an increase
in the clearance of soluble Ab, a reduction in the forma-
tion of an insoluble Ab fibrillar matrix, and a decrease of
the toxicity of Ab to cells. This study provides one mecha-
nism for regulating Ab accumulation.
Our data, showing that Ab binds to a5b1, and to a lesser
extent avb1, is in agreement with previous reports that Ab
mediates cell attachment, and that the RHD sequence in it
serves as an integrin-binding site (Ghiso et al., 1992; Sabo
et al., 1995). The RHD sequence apparently functions as a
mimic of the RGD sequence in fibronectin, the matrix
ligand of a5b1 (Ruoslahti, 1996a), because a short peptide
containing the RGD sequence inhibits Ab binding. a5b1
binds only to nonfibrillar Ab, since we did not see any de-
tectable cell adhesion to aggregated fibrillar Ab. There-
fore, other receptors presumably mediate cellular inter-
actions with fibrillar Ab, and are responsible for the
cytotoxic effects of this form of Ab. The a5b1 integrin is
one of the most discriminating of the RGD-directed in-
tegrins with regard to its ligand specificity (Ruoslahti,
1996b). In addition to its main ligand fibronectin, the a5b1
integrin has only been shown to bind to the bacterial pro-
tein invasin (Watari et al., 1996) and the insulin-like
growth factor binding protein IGFBP-X (Jones et al.,
Figure 6. a5b1-expressing cells take up and
degrade soluble Ab. (A) Cell-associated 125I-
labeled Ab1-40 in CHO-B2/c control cells
and  a5b1-expressing CHO-B2 cells. Cell cul-
tures were incubated for 1 h with soluble 125I-
labeled Ab1-40, detached with EDTA, and
solubilized with NP40 representing both cell-
associated and internalized Ab. (B) Degrada-
tion of 125I-labeled Ab1-40 in IMR-32 control
cells and a5b1-expressing clones. The cul-
tures were incubated with soluble 125I-labeled
Ab1-40 over a 72-h period, and cells were de-
tached with EDTA, solubilized with NP40, and
the NP40 extracts were precipitated with trichlo-
roacetic acid (TCA) to separate 125I-labeled Ab
into a degraded soluble fraction and an insol-
uble fraction representing intact or partially
degraded Ab. (C) Cell-associated 125I-labeled
Ab1-40 in CHO control cells (CHO-B2/c) and a5b1-expressing clones (CHO-B2/a5b1). (D and E) Release of [125I] from 125I-labeled
Ab1-40 into cell culture medium. 125I-labeled soluble Ab1-40 was added to the culture media of various IMR-32 (D) or CHO (E) cell
lines and incubated for 1 h. After that, the media was removed, the cell layer was washed, and new media was added. The release of ra-
dioactivity into the media was monitored over a 72-h period. Experiments in A–E were repeated at least three times, and representative
results are shown. Values in A–E represent the mean 6 SD; n 5 3.Matter et al. Integrin Mediated Internalization of Soluble Amyloid-b 1027
1993). Our results add Ab among its ligands. The binding
site for a5b1 seems to be available only in Ab, not in its
precursor protein (APP; B. Bossy, M.L. Matter, and E.
Ruoslahti, unpublished results).
The a5b1 integrin may play a role in the rapid clearance
of Ab that occurs in the normal brain (Ghersi-Egea et al.,
1996). We show that expression of the a5b1 integrin is as-
sociated with increased cellular uptake and degradation
and decreased matrix deposition of Ab in cell cultures.
Moreover, reversal of this effect with a function-blocking
anti-a5 antibody established a causal link between a5b1
activity and increased clearance of Ab. Although more
complex explanations of this effect are possible, the bind-
ing of Ab to a5b1 shown here suggests that Ab binds to
a5b1 at the cell surface, and is subsequently internalized
into a cellular compartment where it is degraded. This hy-
pothesis is in agreement with previous results showing that
a neuronal cell line internalizes Ab from culture medium
in a manner that is dependent on the NH2 terminus of Ab
where the RHD sequence resides (Ida et al., 1996). The li-
poprotein Apo J can also reduce the formation of fibrillar
Ab by causing it to be internalized and degraded (Hammad
et al., 1997). Thus, it is likely that more than one mecha-
nism plays a role in the regulation of Ab accumulation in
vivo. Clearly, a transgenic animal expressing the amyloid
precursor protein with a mutated RHD sequence would
be of great interest in testing the contribution of the RHD
sequence and integrin-binding to the metabolism of Ab.
The a5b1 integrin circulates through the endocytic cycle
(Bretscher, 1989; Bretscher, 1992). Inhibiting exocytosis
with primaquin causes accumulation of internalized a5b1
in an intracellular pool that returns to the cell surface over
time. Recent studies have shown that internalization of
fibrillar Ab promotes accumulation of stable fibrillar Ab
in the late endosome/secondary lysosome compartment,
whereas internalization of soluble Ab leads to degradation
of the peptide in the same compartment (Knauer et al.,
1992; Koo and Squazzo, 1994; Yang et al., 1995). This re-
sult is in agreement with our data, showing that soluble Ab
is internalized through an a5b1 integrin-mediated path-
way, and is at least partially degraded, presumably within
endosomes. Thus, clearance of soluble Ab can be mediated
by the a5b1 integrin, presumably through the receptor-
Figure 7. Effect of Ab matrix on apoptosis. Expression of a5b1
protects IMR-32 neuroblastoma cells from apoptosis induced by
Ab matrix formation. Cell cultures were incubated for 72 h with
Ab1-40 to allow aggregation of Ab into a matrix, and the cultures
were then examined for evidence of cytotoxicity by using the
TUNEL assay. A percentage of IMR-32/c (A) and IMR-32/p (B)
cells underwent apoptosis (green). The viable cells (red) are
counterstained with propidium iodide. No apoptotic cells were
seen in IMR-32/a5b1 transfectant clones 4 (C) and 15 (D) under
the same conditions. (E–F) The IMR-32/c and IMR-32/p control
cells remained viable when incubated for 72 h with the inactive
control peptide Ab40-1. These experiments were repeated at
least three times for each cell line, and representative results are
shown. Bar, 50 mm.
Figure 8. Effect of Ab matrix on apoptosis. Expression of a5b1
protects IMR-32 neuroblastoma cells from apoptosis induced by
Ab matrix formation. Cell cultures were incubated for 72 h with
Ab1-40 to allow aggregation of Ab into a matrix, and the cultures
were then examined for evidence of apoptosis by measuring the
ability of cells to take up acridine orange/ethidium bromide. A
higher percentage of a5b12IMR-32/c and IMR-32/p cells than
a5b11 transfectants underwent apoptosis. Values represent the
mean 6 SD; n 5 9.The Journal of Cell Biology, Volume 141, 1998 1028
mediated endocytosis pathway that normally internalizes
this integrin.
a5b1 may play a protective role in the brain by sup-
pressing Ab cytotoxicity. We provide evidence for two
separate mechanisms that could be responsible for such a
protective effect. First, we show that a5b1-mediated adhe-
Figure 9. Effect of Ab1-40 on cell viability. Cell survival in cul-
tures containing aggregated Ab. Cell cultures were incubated for
72 h with Ab1-40 to allow aggregation of Ab into a matrix, and
the cultures were then examined for their ability to reduce MTT.
(A) The control cells—IMR-32/c (circles) and IMR-32/p (trian-
gles)—lost the ability to reduce MTT, whereas the IMR-32/a5b1
clones 4 (diamonds) and 15 (squares) were essentially resistant
under the same conditions. Values represent the mean 6 SD; n 5
9. (B) The control peptide Ab40-1 did not affect the ability of any
cell type to reduce MTT.
Figure 10. Cell survival in cultures containing aggregated Ab.
Cell cultures were incubated for 72 h with Ab1-40 to allow aggre-
gation of Ab into a matrix, and the LDH levels within the cul-
tures were analyzed. (A) The a5b12 cells IMR-32/c and IMR-32/p
showed increased LDH levels, whereas the IMR-32/a5b1 clones
4, 15, and 16 maintained LDH levels similar to those seen in the
presence of the Ab40-1 control peptide. Values represent the
mean 6 SD; n 5 9. (B) Cell survival on Ab coated from freshly
made solution onto a plastic surface. Cells were seeded onto
Ab1-40, fibronectin, and vitronectin coated onto microtiter wells,
cultured in serum-free conditions, and examined by DAPI stain-
ing after 96 h. The a5b1 transfectants remained viable on Ab1-40
and fibronectin, but not on vitronectin.Matter et al. Integrin Mediated Internalization of Soluble Amyloid-b 1029
sion to nonfibrillar Ab protects cells from apoptosis in cell
culture. Upregulation of Bcl-2 (Zhang et al., 1995) and ac-
tivation of the MAPK pathway (Wary et al., 1997) may be
responsible for this pathway. The second and potentially
more important mechanism is suggested by our demon-
stration that a5b1 suppresses the apoptotic effects of Ab
by reducing production of toxic Ab matrix.
The a5b1 integrin and avb1 are present in the adult cen-
tral nervous system (Grooms et al., 1993). Immunostaining
for a5b1 shows that it is expressed in the vasculature, cor-
tex, and hippocampus of adult rat brain (Bahr et al., 1991;
Pagani et al., 1992; Tawil et al., 1994; for review see Sar-
gent Jones, 1996). Moreover, primary hippocampal neu-
rons express a5b1 (Yamazaki et al., 1997). Soluble Ab1-40
is present in vivo (Seubert et al., 1992), and is rapidly
cleared when injected into normal rats (Ghersi-Egea et al.,
1996). Our results suggest that a5b1 may mediate the
clearance of Ab, and that a5b1 may play a significant role
in protecting the brain from the Ab-initiated pathology
that in its extreme form causes AD.
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